Stephan Devriese
Overview
Explore the profile of Stephan Devriese including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
26
Citations
226
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Odnoletkova I, Chalon P, Devriese S, Cleemput I
Pharmacoeconomics
. 2025 Jan;
PMID: 39798038
Background: Forecasting future public pharmaceutical expenditure is a challenge for healthcare payers, particularly owing to the unpredictability of new market introductions and their economic impact. No best-practice forecasting methods have...
2.
Neyt M, de Meester C, Devriese S, Marynen E, Beeckman D
J Tissue Viability
. 2024 Sep;
33(4):772-777.
PMID: 39261271
Objectives: To estimate the cost-effectiveness of sacrum multilayer silicone foam dressings as an adjuvant prophylactic therapy compared to standard pressure ulcer prevention in a hospital population at high risk for...
3.
Bouckaert N, Cleemput I, Devriese S, Gerkens S
Pharmacoecon Open
. 2022 Aug;
6(6):823-836.
PMID: 35927410
Objective: This study aimed to establish a Belgian EQ-5D-5L value set based on the preferences of the adult Belgian general population. Methods: The most recent EuroQol Valuation Technology (EQ-VT 2.1)...
4.
Cleemput I, Devriese S, Kohn L, Devos C, van Til J, Groothuis-Oudshoorn C, et al.
MDM Policy Pract
. 2022 Feb;
3(2):2381468318799628.
PMID: 35187243
Multi-criteria decision analysis can improve the legitimacy of health care reimbursement decisions by taking societal preferences into account when weighting decision criteria. This study measures the relative importance of health...
5.
de Meester C, Bourgeois J, Devriese S, San Miguel L
Int Arch Allergy Immunol
. 2021 Jun;
182(11):1127-1134.
PMID: 34192688
Introduction: Worldwide, polyvalent immunoglobulin (Ig) use is rising. Together with the limited supply, this puts pressure on Ig availability. A clear overview on a country's usage pattern helps in forecasting...
6.
Cleemput I, Devriese S, Kohn L, Westhovens R
Health Policy
. 2018 Jul;
122(8):878-884.
PMID: 29983193
Early temporary reimbursement (ETR) schemes for new interventions targeting high unmet needs are increasingly applied in pharmaceutical policy. Crucial for these schemes is the assessment of unmet healthcare needs of...
7.
Neyt M, Vlayen J, Devriese S, Camberlin C
PLoS One
. 2018 Apr;
13(4):e0195134.
PMID: 29630612
Background: Currently, in Belgium, bevacizumab is reimbursed for ovarian cancer patients, based on a contract between the Minister and the manufacturer including confidential agreements. This reimbursement will be re-evaluated in...
8.
Van den Heede K, Quentin W, Dubois C, Devriese S, Van de Voorde C
Health Policy
. 2017 Feb;
121(4):339-345.
PMID: 28222904
Internationally the number of emergency department (ED) visits is on the rise while evidence suggests that a substantial proportion of these patients do not require emergency care but primary care....
9.
Neyt M, Van Brabandt H, Devriese S, Van De Sande S
BMJ Open
. 2012 May;
2(3).
PMID: 22561354
Background: Patients with severe aortic stenosis and coexisting non-cardiac conditions may be at high risk for surgical replacement of the aortic valve or even be no candidates for surgery. In...
10.
Gerkens S, Gailly J, Obyn C, Devriese S, Cleemput I
J Thromb Thrombolysis
. 2012 Mar;
34(3):300-9.
PMID: 22437654
To examine the cost and cost-effectiveness of the use of point-of-care (POC) devices by the general practitioner (GP), in anticoagulation clinic or by the patient in self-testing (PST) and self-management...